

February 9, 2026

Q3FY26 Result Update

☑ Change in Estimates | ☑ Target | ■ Reco

Change in Estimates

	Current		Previous	
	FY27E	FY28E	FY27E	FY28E
Rating	ACCUMULATE		ACCUMULATE	
Target Price	697		746	
Sales (Rs. m)	9,993	11,613	10,159	11,805
% Chng.	(1.6)	(1.6)		
EBITDA (Rs. m)	2,073	2,445	2,008	2,374
% Chng.	3.2	3.0		
EPS (Rs.)	28.7	36.9	27.6	35.9
% Chng.	3.8	3.0		

Key Financials - Standalone

Y/e Mar	FY25	FY26E	FY27E	FY28E
Sales (Rs. m)	7,813	8,658	9,993	11,613
EBITDA (Rs. m)	1,417	1,714	2,073	2,445
Margin (%)	18.1	19.8	20.7	21.1
PAT (Rs. m)	606	716	953	1,227
EPS (Rs.)	18.3	21.5	28.7	36.9
Gr. (%)	(8.9)	18.0	33.1	28.8
DPS (Rs.)	2.0	4.0	6.0	7.0
Yield (%)	0.4	0.7	1.1	1.3
RoE (%)	9.8	10.7	13.0	14.9
RoCE (%)	12.1	13.4	16.0	18.4
EV/Sales (x)	2.5	2.3	2.0	1.7
EV/EBITDA (x)	14.0	11.5	9.4	7.9
PE (x)	29.9	25.3	19.0	14.8
P/BV (x)	2.8	2.6	2.3	2.1

Key Data

MOLT.BO | MTEP IN

52-W High / Low	Rs.893 / Rs.410
Sensex / Nifty	84,066 / 25,867
Market Cap	Rs.18bn/ \$ 200m
Shares Outstanding	33m
3M Avg. Daily Value	Rs.31.85m

Shareholding Pattern (%)

Promoter's	33.07
Foreign	20.12
Domestic Institution	10.36
Public & Others	36.45
Promoter Pledge (Rs bn)	-

Stock Performance (%)

	1M	6M	12M
Absolute	(7.0)	(30.8)	(12)
Relative	(7.6)	(34.3)	(8.5)

Vishwa Solanki

vishwasolanki@plindia.com | 91-22-66322244

Amnish Aggarwal

amnishaggarwal@plindia.com | 91-22-66322233

Parth Thakker

parththakker@plindia.com |

Near term outlook healthy, Paints to drive growth

Quick Pointers:

- Pharma sales to clock Rs500mn+ in value for FY27
- EBITDA growth for FY27 to come at ~20+%

We increase our FY27/FY28 estimate by 3.8%/3.0% led by 1) healthy demand outlook in near term with double digit volume growth guidance. 2) Improving capacity utilization with 70%+ expected for FY27 3) strong demand in pharma and pick up in Lubes from FY27 onwards and 4) healthy order flow outlook from ABG. MTEP revenue were miss on our estimates amidst extended monsoon and shorter festive period while PAT were beat led by healthy GM and lower other expenses. EBITDA/kg came in at Rs40.3(Adjusted of labour code impact) vs Rs39/Rs36.5 in 2Q26/3Q25

We believe LT drivers for MTEP remain intact given 1) rising business from leading paint & FMCG companies, visible recovery in lubes, and scale up in pharma business. 2) Company received incremental orders from new customers, with more than seven orders during Q3. & 3) Capacity enhancements at Cheyyar and Panipat with growing demand from ABG will enable increase in capacity utilization from Q4FY26 onwards. We estimate EBITDA/kg to increase to Rs44.7/47.3 over FY27 and FY28. We estimate a 15.8% Sales CAGR & 30.9% EPS CAGR over FY26-FY28. We assign a PE of 20x on Dec27 valuing the company at Rs697. Retain 'Accumulate'.

Sales grew 4.1%, Volumes grew 5.9%: Revenues grew by 4.1% YoY to Rs2bn (PLe: Rs2.078bn). Gross margins expanded by 196bps YoY to 47.1% (PLe: 45.2%). EBITDA grew by 16.8% YoY to Rs395mn (PLe:Rs391mn); Margins expanded by 217bps YoY to 19.9% (PLe:18.8%). Adj PAT grew by 13.1% YoY to Rs154mn (PLe:Rs149mn)

Concall Takeaways: 1) Q3 demand remained impacted due to shorter festive season and extended rainfall. 2) Demand remained strong in January, delivering double-digit volume growth, while February continues to see a healthy order book. 3) ABG volume grew by 21% in Q3, while APNT is picking up good led by increasing RCCB adoption. 4) Pharma revenue is likely to cross Rs320mn in FY26, while it is expected to reach Rs~500mn by FY27 led by entry into Eye- droppers, Nasal spray and 28 CRC closures. 5)FY26 volume guidance trimmed to ~41–42k, FY26 revenue exit guided at ~Rs8.7bn. 6) FY27 outlook constructive: management targets Rs10bn revenue with 12–15% volume growth. 7) Volumes in lubes declined due to exit from low-margin PSU tenders (BPCL) and non-participation in low-grade DEF products. 8) Capex for FY26 to come at Rs1200mn, while for FY27 it is expected to be at Rs80–85mn with 20–25mn to be utilized for Pharma 9) Capacity utilization from last two quarters remained at 62.5%, however it is improving and likely to go above 70% in near to medium term. 10)Panipat plant ramp-up progressing well with 8–10 active clients, expected to double over the next season. 11)25+ pharma clients have approved facilities, with more yet to scale commercial volumes. 12) MOU with Swiggy for restaurant and food pack will improve reach across food delivery ecosystem.

Exhibit 1: Sales up 4.1% YoY, EBITDA margins up by 217bps YoY

Y/e March	Q3FY26	Q3FY25	YoY gr. (%)	Q2FY26	9MFY26	9MFY25	YoY gr. (%)
Net Sales	1,984	1,907	4.1	2,098	6,488	5,787	12.1
Gross Profit	935	861	8.6	959	2,958	2,528	17.0
% of NS	47.1	45.1	1.96	45.7	45.6	43.7	1.9
Other Expenses	540	523	3.3	567	1,704	1,497	13.8
% of NS	27.2	27.4	(0.21)	27.1	26.3	25.9	0.4
EBITDA	395	338	16.8	391	1,254	1,031	21.6
Margins %	19.9	17.7	2.17	18.6	19.3	17.8	1.5
Depreciation	152	124	22.5	145	437	359	21.8
Interest	44	34	29.0	42	128	99	29.5
Other Income	2	2	50.1	4	12	17	(27.0)
PBT	191	182	5.0	208	699	590	18.4
Tax	47	45	4.5	53	177	148	19.8
Tax rate %	24.8	24.9	(0.12)	25.6	25.3	25.0	0.3
Adjusted PAT	154	136	13.1	155	525	443	18.5


Source: Company, PL

Exhibit 2: Overall volume went up by 5.9% in 3QFY26, Paints up 8.0%, F&F 21.7% and lubes decline 19.7%

Y/E Mar	4Q24	1Q25	2Q25	3Q25	4Q25	1Q26	2Q26	3Q26
Volumes	9,071	9,894	9,381	9,247	9,734	11,378	10,018	9,808
YoY Change (%)	0.0	7.5	6.9	7.5	7.3	15.0	6.8	5.9
EBIDTA/ Kg	39.1	36.1	35.8	36.6	39.3	41.1	39.0	40.3
Growth %	-0.4%	-5.2%	-2.3%	3.8%	0.5%	13.9%	9.1%	10.3%
Realization	-4.3	-1.7	5.4	7.7	7.2	7.3	2.9	-1.9
Paints	4200	4483	4688	4439	4413	5593	4845	4795
Growth %	-10.4	1.5	5.1	16.8	5.1	24.8	3.4	8.0
Volume Share	46.3%	45.4%	49.4%	48.7%	46.0%	49.2%	49.6%	49.8%
Lubes	2350	2574	2052	2090	2455	2398	1776	1679
Growth %	-1.9	-0.2	-5.1	-7.9	4.5	-6.8	-13.5	-19.7
Volume Share	25.9%	26.1%	21.6%	22.9%	25.6%	21.1%	18.2%	17.4%
F&F	2521	2818	2745	2589	2717	3196	3141	3151
Growth %	26.9	26.7	27.3	2.3	7.8	13.4	14.4	21.7
Volume Share	27.8%	28.5%	28.9%	28.4%	28.3%	28.1%	32.2%	32.7%
Total Volume Tons	9071	9875	9486	9118	9585	11187	9762	9625
Vol Growth	0.0%	7.1%	8.0%	6.0%	5.7%	13.3%	2.9%	5.6%
Realization Growth	-4.3%	-1.3%	4.2%	9.3%	8.9%	9.0%	6.7%	-1.5%
Sales per kg (Rs)	195	199	202	209	211	215	215	206


Source: Company, PL

Exhibit 3: Paints business increased to 45.3% from 44.1%



Source: Company, PL

Exhibit 4: EBITDA/Kg (Adj of Labour impact) Rs 40.3 in 3Q26



Source: Company, PL

Financials

Income Statement (Rs m)

Y/e Mar	FY25	FY26E	FY27E	FY28E
Net Revenues	7,813	8,658	9,993	11,613
YoY gr. (%)	11.8	10.8	15.4	16.2
Cost of Goods Sold	4,523	4,727	5,449	6,318
Gross Profit	3,291	3,932	4,544	5,295
Margin (%)	42.1	45.4	45.5	45.6
Employee Cost	609	684	769	894
Other Expenses	-	-	1	1
EBITDA	1,417	1,714	2,073	2,445
YoY gr. (%)	6.4	20.9	20.9	18.0
Margin (%)	18.1	19.8	20.7	21.1
Depreciation and Amortization	487	596	654	705
EBIT	930	1,118	1,419	1,740
Margin (%)	11.9	12.9	14.2	15.0
Net Interest	139	173	160	121
Other Income	22	16	19	21
Profit Before Tax	814	961	1,278	1,639
Margin (%)	10.4	11.1	12.8	14.1
Total Tax	207	245	326	413
Effective tax rate (%)	25.5	25.5	25.5	25.2
Profit after tax	606	716	952	1,226
Minority interest	-	-	-	-
Share Profit from Associate	-	-	-	-
Adjusted PAT	606	716	953	1,227
YoY gr. (%)	(8.9)	18.0	33.1	28.8
Margin (%)	7.8	8.3	9.5	10.6
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	606	716	953	1,227
YoY gr. (%)	(8.9)	18.0	33.1	28.8
Margin (%)	7.8	8.3	9.5	10.6
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	606	716	953	1,227
Equity Shares O/s (m)	33	33	33	33
EPS (Rs)	18.3	21.5	28.7	36.9

Source: Company Data, PL Research

Balance Sheet Abstract (Rs m)

Y/e Mar	FY25	FY26E	FY27E	FY28E
Non-Current Assets				
Gross Block	7,610	8,810	9,610	10,360
Tangibles	7,562	8,759	9,556	10,303
Intangibles	48	51	54	57
Acc: Dep / Amortization	2,181	2,777	3,432	4,139
Tangibles	2,154	2,745	3,395	4,096
Intangibles	27	32	37	43
Net fixed assets	5,430	6,033	6,178	6,222
Tangibles	5,408	6,014	6,161	6,207
Intangibles	21	19	17	14
Capital Work In Progress	304	150	200	200
Goodwill	-	-	-	-
Non-Current Investments	329	174	160	406
Net Deferred tax assets	(270)	(295)	(327)	(369)
Other Non-Current Assets	283	289	297	308
Current Assets				
Investments	-	-	1	1
Inventories	1,286	1,165	1,344	1,558
Trade receivables	1,353	1,660	1,916	2,227
Cash & Bank Balance	18	39	25	31
Other Current Assets	272	272	313	363
Total Assets	9,368	9,878	10,544	11,442
Equity				
Equity Share Capital	166	166	166	166
Other Equity	6,213	6,794	7,548	8,542
Total Network	6,379	6,961	7,714	8,708
Non-Current Liabilities				
Long Term borrowings	694	700	500	200
Provisions	77	87	98	114
Other non current liabilities	57	53	53	53
Current Liabilities				
ST Debt / Current of LT Debt	1,063	950	900	900
Trade payables	444	414	478	554
Other current liabilities	384	419	473	544
Total Equity & Liabilities	9,369	9,879	10,543	11,442

Source: Company Data, PL Research

Cash Flow (Rs m)

Y/e Mar	FY25	FY26E	FY27E	FY28E
PBT	814	961	1,279	1,640
Add. Depreciation	470	591	650	701
Add. Interest	139	173	160	121
Less Financial Other Income	22	16	19	21
Add. Other	28	9	8	18
Op. profit before WC changes	1,450	1,734	2,096	2,480
Net Changes-WC	(110)	(184)	(372)	(446)
Direct tax	(207)	(245)	(326)	(413)
Net cash from Op. activities	1,133	1,305	1,398	1,621
Capital expenditures	(1,406)	(1,031)	(836)	(737)
Interest / Dividend Income	22	16	18	20
Others	70	145	16	(244)
Net Cash from Invst. activities	(1,314)	(870)	(802)	(961)
Issue of share cap. / premium	(72)	(68)	(66)	(33)
Debt changes	494	(107)	(250)	(300)
Dividend paid	(100)	(66)	(133)	(199)
Interest paid	(139)	(173)	(160)	(121)
Others	-	-	1	1
Net cash from Fin. activities	184	(414)	(608)	(653)
Net change in cash	3	21	(12)	7
Free Cash Flow	(273)	274	562	884

Source: Company Data, PL Research

Key Financial Metrics

Y/e Mar	FY25	FY26E	FY27E	FY28E
Per Share(Rs)				
EPS	18.3	21.5	28.7	36.9
CEPS	32.9	39.5	48.4	58.1
BVPS	192.0	209.5	232.1	262.1
FCF	(8.2)	8.2	16.9	26.6
DPS	2.0	4.0	6.0	7.0
Return Ratio(%)				
RoCE	12.1	13.4	16.0	18.4
ROIC	9.1	10.0	12.0	13.8
RoE	9.8	10.7	13.0	14.9
Balance Sheet				
Net Debt : Equity (x)	0.3	0.2	0.2	0.1
Net Working Capital (Days)	102	102	102	102
Valuation(x)				
PER	29.9	25.3	19.0	14.8
P/B	2.8	2.6	2.3	2.1
P/CEPS	16.6	13.8	11.3	9.4
EV/EBITDA	14.0	11.5	9.4	7.9
EV/Sales	2.5	2.3	2.0	1.7
Dividend Yield (%)	0.4	0.7	1.1	1.3


Source: Company Data, PL Research

Quarterly Financials (Rs m)

Y/e Mar	Q4FY25	Q1FY26	Q2FY26	Q3FY26
Net Revenue	2,026	2,406	2,098	1,984
YoY gr. (%)	14.6	22.3	9.6	4.1
Raw Material Expenses	1,144	1,341	1,139	1,050
Gross Profit	882	1,065	959	935
Margin (%)	43.6	44.3	45.7	47.1
EBITDA	383	468	391	395
YoY gr. (%)	7.9	31.0	16.5	16.8
Margin (%)	18.9	19.4	18.6	19.9
Depreciation / Depletion	128	140	145	152
EBIT	255	327	246	243
Margin (%)	12.6	13.6	11.7	12.3
Net Interest	40	42	42	44
Other Income	8	6	4	2
Profit before Tax	222	292	208	202
Margin (%)	11.0	12.1	9.9	10.2
Total Tax	60	76	53	47
Effective tax rate (%)	26.8	26.1	25.6	23.5
Profit after Tax	163	216	155	154
Minority interest	-	-	-	-
Share Profit from Associates	-	-	-	-
Adjusted PAT	163	216	155	154
YoY gr. (%)	(9.5)	30.5	9.7	13.1
Margin (%)	8.0	9.0	7.4	7.8
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	163	216	155	154
YoY gr. (%)	(9.5)	30.5	9.7	13.1
Margin (%)	8.0	9.0	7.4	7.8
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	163	216	155	154
Avg. Shares O/s (m)	28	28	28	28
EPS (Rs)	5.9	7.8	5.6	5.6

Source: Company Data, PL Research

Price Chart



Recommendation History

No.	Date	Rating	TP (Rs.)	Share Price (Rs.)
1	08-Jan-26	Accumulate	746	608
2	29-Oct-25	Accumulate	782	733
3	08-Oct-25	Accumulate	821	761
4	28-Jul-25	Accumulate	805	761
5	09-Jul-25	Accumulate	723	704
6	20-May-25	Accumulate	636	565
7	09-Apr-25	Accumulate	621	470

Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Kansai Nerolac Paints	Accumulate	248	222
2	Mold-tek Packaging	Accumulate	782	733

PL's Recommendation Nomenclature (Absolute Performance)

Buy	: > 15%
Accumulate	: 5% to 15%
Hold	: +5% to -5%
Reduce	: -5% to -15%
Sell	: < -15%
Not Rated (NR)	: No specific call on the stock
Under Review (UR)	: Rating likely to change shortly

ANALYST CERTIFICATION

(Indian Clients)

We/I, Mr. Vishwa Solanki- PGDM - Finance, Mr. Amnish Aggarwal- MBA, CFA, Mr. Parth Thakker- BFM, Passed CFA Level II Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

(US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Vishwa Solanki- PGDM - Finance, Mr. Amnish Aggarwal- MBA, CFA, Mr. Parth Thakker- BFM, Passed CFA Level II Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209

www.plindia.com